$BLUE
bluebird bio, Inc. Stock $blue

$blue Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000129397120000029 Filed on May 11, 2020

Income Statement

Concept	2020 Q1	2019 Q1
Revenue	$0.00	$12.47M
YoY Change	-100.0%	-21.85%
Cost Of Revenue	$1.025M	$430.0K
YoY Change	138.37%	2429.41%
Gross Profit	-$1.025M	$12.04M
YoY Change	-108.51%	-24.46%
Gross Profit Margin		96.55%
Selling, General & Admin	$73.25M	$60.28M
YoY Change	21.51%	72.72%
% of Gross Profit		500.61%
Research & Development	$154.1M	$122.6M
YoY Change	25.67%	26.3%
% of Gross Profit		1018.52%
Depreciation & Amortization	$4.880M	$3.780M
YoY Change	29.1%	-5.97%
% of Gross Profit		31.39%
Operating Expenses	$227.4M	$182.9M
YoY Change	24.3%	37.96%
Operating Profit	-$144.5M	-$171.2M
YoY Change	-15.6%	46.77%
Interest Expense	$5.355M	$10.10M
YoY Change	-46.99%	627.81%
% of Operating Profit
Other Income/Expense, Net	-$4.447M	-$3.389M
YoY Change	31.22%	-3046.96%
Pretax Income	-$202.5M	-$164.5M
YoY Change	23.14%	42.85%
Income Tax	$94.00K	-$15.00K
% Of Pretax Income
Net Earnings	-$202.6M	-$164.4M
YoY Change	23.21%	42.84%
Net Earnings / Revenue		-1318.63%
Basic Earnings Per Share	-$3.64
Diluted Earnings Per Share	-$3.64	-$2.989M
COMMON SHARES
Basic Shares Outstanding	55.61M shares	54.95M
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.018B	$1.731B
YoY Change	-41.16%	54.31%
Cash & Equivalents	$346.6M	$221.7M
Short-Term Investments	$671.7M	$1.509B
Other Short-Term Assets	$54.40M	$39.40M
YoY Change	38.07%	-7.29%
Inventory
Prepaid Expenses	$40.21M
Receivables	$2.400M	$3.800M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$967.5M	$1.365B
YoY Change	-29.12%	17.26%
LONG-TERM ASSETS
Property, Plant & Equipment	$153.9M	$298.6M
YoY Change	-48.45%	46.23%
Goodwill	$13.13M
YoY Change
Intangibles	$13.25M
YoY Change
Long-Term Investments	$107.7M	$408.9M
YoY Change	-73.66%	-8.07%
Other Assets	$79.19M	$40.60M
YoY Change	95.05%	65.04%
Total Long-Term Assets	$561.6M	$773.6M
YoY Change	-27.4%	10.09%
TOTAL ASSETS
Total Short-Term Assets	$967.5M	$1.365B
Total Long-Term Assets	$561.6M	$773.6M
Total Assets	$1.529B	$2.139B
YoY Change	-28.5%	14.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$30.53M	$30.20M
YoY Change	1.08%	151.67%
Accrued Expenses	$115.5M	$63.00M
YoY Change	83.33%	4.83%
Deferred Revenue	$6.355M	$11.49M
YoY Change	-44.69%	-74.66%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00
YoY Change		-100.0%
Total Short-Term Liabilities	$184.4M	$146.7M
YoY Change	25.71%	36.09%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$2.784M	$219.8M
YoY Change	-98.73%	540.82%
Total Long-Term Liabilities	$2.784M	$219.8M
YoY Change	-98.73%	16.42%
TOTAL LIABILITIES
Total Short-Term Liabilities	$184.4M	$146.7M
Total Long-Term Liabilities	$2.784M	$219.8M
Total Liabilities	$408.7M	$366.5M
YoY Change	11.51%	23.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.480B
YoY Change
Common Stock	$556.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.120B	$1.772B
YoY Change
Total Liabilities & Shareholders Equity	$1.529B	$2.139B
YoY Change	-28.5%	14.56%

Cashflow Statement

Concept	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	-$202.6M	-$164.4M
YoY Change	23.21%	42.84%
Depreciation, Depletion And Amortization	$4.880M	$3.780M
YoY Change	29.1%	-5.97%
Cash From Operating Activities	-$206.1M	-$154.2M
YoY Change	33.71%	41.66%
INVESTING ACTIVITIES
Capital Expenditures	$10.68M	$19.32M
YoY Change	-44.74%	159.27%
Acquisitions
YoY Change
Other Investing Activities	$235.3M	-$17.59M
YoY Change	-1437.41%	-93.16%
Cash From Investing Activities	$224.6M	-$36.91M
YoY Change	-708.4%	-86.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$963.0K	$10.22M
YoY Change	-90.58%	-85.74%
NET CHANGE
Cash From Operating Activities	-$206.1M	-$154.2M
Cash From Investing Activities	$224.6M	-$36.91M
Cash From Financing Activities	$963.0K	$10.22M
Net Change In Cash	$19.42M	-$180.8M
YoY Change	-110.74%	-40.09%
FREE CASH FLOW
Cash From Operating Activities	-$206.1M	-$154.2M
Capital Expenditures	$10.68M	$19.32M
Free Cash Flow	-$216.8M	-$173.5M
YoY Change	24.97%	49.2%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q1	dei	City Area Code CityAreaCode	339
CY2020Q1	dei	Local Phone Number LocalPhoneNumber	499-9300
CY2020Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value per share
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001293971
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2020Q1	dei	Entity File Number EntityFileNumber	001-35966
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	bluebird bio, Inc.
CY2020Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	13-3680878
CY2020Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	60 Binney Street
CY2020Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2020Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2020Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02142
CY2020Q1	dei	Trading Symbol TradingSymbol	BLUE
CY2020Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	55652110	shares
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	346629000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	327214000	USD
CY2020Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	564054000	USD
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	779246000	USD
CY2020Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	40209000	USD
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	32888000	USD
CY2020Q1	blue	Receivables And Other Current Assets ReceivablesAndOtherCurrentAssets	16575000	USD
CY2019Q4	blue	Receivables And Other Current Assets ReceivablesAndOtherCurrentAssets	12826000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	967467000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	1152174000	USD
CY2020Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	107674000	USD
CY2019Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	131506000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	153920000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	151176000	USD
CY2020Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	13254000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	14326000	USD
CY2020Q1	us-gaap	Goodwill Goodwill	13128000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	13128000	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	194469000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	185885000	USD
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	79192000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	79229000	USD
CY2020Q1	us-gaap	Assets Assets	1529104000	USD
CY2019Q4	us-gaap	Assets Assets	1727424000	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	30527000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	42995000	USD
CY2020Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	118091000	USD
CY2019Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	141556000	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	20380000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	20175000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6355000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	8474000	USD
CY2020Q1	blue	Collaboration Research Advancement Current CollaborationResearchAdvancementCurrent	9069000	USD
CY2019Q4	blue	Collaboration Research Advancement Current CollaborationResearchAdvancementCurrent	10380000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	184422000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	223580000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	9791000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	9791000	USD
CY2020Q1	blue	Collaboration Research Advancement Non Current CollaborationResearchAdvancementNonCurrent	26843000	USD
CY2019Q4	blue	Collaboration Research Advancement Non Current CollaborationResearchAdvancementNonCurrent	27834000	USD
CY2020Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	4869000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7977000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	179962000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	170812000	USD
CY2020Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2784000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2437000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	408671000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	442431000	USD
CY2020Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	10.00
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	10.00
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55620000	shares
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55620000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55368000	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55368000	shares
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	556000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	554000	USD
CY2020Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3607139000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3568184000	USD
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2799000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1893000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2484463000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2281852000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	1120433000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1284993000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1529104000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1727424000	USD
CY2020Q1	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	2302000	USD
CY2019Q1	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	1966000	USD
CY2020Q1	us-gaap	Revenues Revenues	21863000	USD
CY2019Q1	us-gaap	Revenues Revenues	12471000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	154123000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	122640000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	73248000	USD
CY2019Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	60279000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1025000	USD
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	430000	USD
CY2020Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-3108000	USD
CY2019Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	296000	USD
CY2020Q1	us-gaap	Costs And Expenses CostsAndExpenses	225288000	USD
CY2019Q1	us-gaap	Costs And Expenses CostsAndExpenses	183645000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-203425000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-171174000	USD
CY2020Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	5355000	USD
CY2019Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	10102000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4447000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3389000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-202517000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-164461000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	94000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-15000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-202611000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-164446000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.64
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.99
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55590000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54957000	shares
CY2020Q1	blue	Other Comprehensive Income Loss Unrealized Gain Loss On Securities And Foreign Currency Translation Adjustments Arising During Period Tax OtherComprehensiveIncomeLossUnrealizedGainLossOnSecuritiesAndForeignCurrencyTranslationAdjustmentsArisingDuringPeriodTax	0.0	USD
CY2019Q1	blue	Other Comprehensive Income Loss Unrealized Gain Loss On Securities And Foreign Currency Translation Adjustments Arising During Period Tax OtherComprehensiveIncomeLossUnrealizedGainLossOnSecuritiesAndForeignCurrencyTranslationAdjustmentsArisingDuringPeriodTax	400000	USD
CY2020Q1	blue	Other Comprehensive Income Loss Unrealized Gain Loss And Foreign Currency Translation Adjustment On Securities And Pension And Other Postretirement Benefit Plans Arising During Period Net Of Tax OtherComprehensiveIncomeLossUnrealizedGainLossAndForeignCurrencyTranslationAdjustmentOnSecuritiesAndPensionAndOtherPostretirementBenefitPlansArisingDuringPeriodNetOfTax	-906000	USD
CY2019Q1	blue	Other Comprehensive Income Loss Unrealized Gain Loss And Foreign Currency Translation Adjustment On Securities And Pension And Other Postretirement Benefit Plans Arising During Period Net Of Tax OtherComprehensiveIncomeLossUnrealizedGainLossAndForeignCurrencyTranslationAdjustmentOnSecuritiesAndPensionAndOtherPostretirementBenefitPlansArisingDuringPeriodNetOfTax	1835000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-906000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1835000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-203517000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-162611000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1284993000	USD
CY2020Q1	blue	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	0	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	750000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1872000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	36335000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-906000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-202611000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	1120433000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1885070000	USD
CY2019Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	6564000	USD
CY2019Q1	blue	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	0	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9504000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1231000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32341000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1835000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-164446000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	1772099000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-202611000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-164446000	USD
CY2020Q1	blue	Fair Value Of Contingent Consideration Non Cash FairValueOfContingentConsiderationNonCash	-3108000	USD
CY2019Q1	blue	Fair Value Of Contingent Consideration Non Cash FairValueOfContingentConsiderationNonCash	296000	USD
CY2020Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4880000	USD
CY2019Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3783000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	36293000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	32341000	USD
CY2020Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-4520000	USD
CY2019Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-3085000	USD
CY2020Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	1387000	USD
CY2019Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	3456000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	10984000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	12793000	USD
CY2020Q1	blue	Lessee Increase Decrease In Operating Lease Right Of Use Asset LesseeIncreaseDecreaseInOperatingLeaseRightOfUseAsset	5842000	USD
CY2019Q1	blue	Lessee Increase Decrease In Operating Lease Right Of Use Asset LesseeIncreaseDecreaseInOperatingLeaseRightOfUseAsset	5374000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-9519000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	10590000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-20557000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-21514000	USD
CY2020Q1	blue	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-5070000	USD
CY2019Q1	blue	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	3224000	USD
CY2020Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2118000	USD
CY2019Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-8672000	USD
CY2020Q1	blue	Increase Decrease In Collaboration Research Advancement IncreaseDecreaseInCollaborationResearchAdvancement	2302000	USD
CY2019Q1	blue	Increase Decrease In Collaboration Research Advancement IncreaseDecreaseInCollaborationResearchAdvancement	1966000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-206121000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-154154000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10676000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19321000	USD
CY2020Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	101421000	USD
CY2019Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	381735000	USD
CY2020Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	336675000	USD
CY2019Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	364143000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	224578000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-36913000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	963000	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	10223000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	963000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10223000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	19420000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-180844000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	381709000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	417099000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	401129000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	236255000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	346629000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	221738000	USD
CY2020Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	USD
CY2019Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	100000	USD
CY2020Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	54500000	USD
CY2019Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	14417000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	401129000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	236255000	USD
CY2020Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1125000	USD
CY2019Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	9302000	USD
CY2020Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	14425000	USD
CY2019Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5500000	USD
CY2020Q1	blue	Tenant Improvements Included In Tenant Improvements Receivables Including Other Current Assets TenantImprovementsIncludedInTenantImprovementsReceivablesIncludingOtherCurrentAssets	1516000	USD
CY2019Q1	blue	Tenant Improvements Included In Tenant Improvements Receivables Including Other Current Assets TenantImprovementsIncludedInTenantImprovementsReceivablesIncludingOtherCurrentAssets	8009000	USD
CY2020Q1	us-gaap	Nature Of Operations NatureOfOperations	Description of the business<div style="text-indent:18pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">bluebird bio, Inc. (the “Company” or “bluebird”) was incorporated in Delaware on April 16, 1992, and is headquartered in Cambridge, Massachusetts. The Company is a biotechnology company committed to researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases and cancer. Since its inception, the Company has devoted substantially all of its resources to its research and development efforts relating to its product candidates, including activities to manufacture product candidates, conduct clinical studies of its product candidates, perform preclinical research to identify new product candidates and provide selling, general and administrative support for these operations, including commercial-readiness activities.</span></div><div style="text-indent:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company’s programs in severe genetic diseases include ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) gene therapy as a treatment for transfusion-dependent β-thalassemia, or TDT; its LentiGlobin</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> product candidate as a treatment for sickle cell disease, or SCD; and its Lenti-D™ product candidate as a treatment for cerebral adrenoleukodystrophy, or CALD. The Company’s programs in oncology are focused on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Idecabtagene vicleucel, or ide-cel, and bb21217, which are product candidates in oncology under the Company’s collaboration arrangement with Bristol-Myers Squibb ("BMS"), formerly Celgene Corporation ("Celgene") prior to its acquisition by BMS in November 2019, are CAR T cell product candidates for the treatment of multiple myeloma. Please refer to Note 9, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative arrangements,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for further discussion of the Company’s collaboration with BMS.</span></div><div style="text-indent:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2019, the Company received conditional marketing authorization from the European Commission for ZYNTEGLO (formerly referred to as LentiGlobin for TDT) for the treatment of patients 12 years and older with TDT who do not have a β0/β0 genotype, for whom hematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte-matched related HSC donor is not available. Since receiving conditional marketing authorization for ZYNTEGLO, the Company has continued to advance its commercialization readiness activities. Through March 31, 2020, the Company had not generated any revenue from product sales of ZYNTEGLO.</span></div><div style="text-indent:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In accordance with Accounting Standards Codification ("ASC") 205-40, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Going Concern</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. The Company has incurred losses since inception and to date has financed its operations primarily through the sale of shares of the Company's stock and, to a lesser extent, through collaboration agreements and grants from governmental agencies and charitable foundations. As of March 31, 2020, the Company had an accumulated deficit of $2.48 billion. During the three months ended March 31, 2020, the Company incurred a loss of $202.6 million and used $206.1 million of cash in operations. The Company expects to continue to generate operating losses and negative operating cash flows for the next few years and will need additional funding to support its planned operating activities through profitability. The transition to profitability is dependent upon the successful development, approval, and commercialization of the Company’s products and product candidates and the achievement of a level of revenues adequate to support its cost structure. </span></div><div style="text-indent:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March 31, 2020, the Company had cash, cash equivalents and marketable securities of $1.02 billion. The Company expects its cash, cash equivalents and marketable securities will be sufficient to fund current planned operations for at least twelve months from the date of issuance of these financial statements, though it may pursue additional cash resources through public or private equity or debt financings, strategic collaborations or other sources. Management's expectations with respect to its ability to fund current planned operations is based on estimates that are subject to risks and uncertainties. If actual results are different from management's estimates, the Company may need to seek additional strategic or financing opportunities sooner than would otherwise be expected. However, there is no guarantee that any of these strategic or financing opportunities will be executed or executed on favorable terms, and some could be dilutive to existing stockholders. If the Company is unable to obtain additional funding on a timely basis, it may be forced to significantly curtail, delay, or discontinue one or more of its planned research or development programs or be unable to expand its operations or otherwise capitalize on its commercialization of its product candidates.</span></div>
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2480000000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-202600000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-206100000	USD
CY2020Q1	us-gaap	Investments And Cash InvestmentsAndCash	1020000000.00	USD
CY2020Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2019Q4	blue	Marketable Securities Amortized Cost MarketableSecuritiesAmortizedCost	915152000	USD
CY2019Q4	blue	Marketable Securities Unrealized Gains MarketableSecuritiesUnrealizedGains	2838000	USD
CY2019Q4	blue	Marketable Securities Unrealized Loss MarketableSecuritiesUnrealizedLoss	7238000	USD
CY2020Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of estimates</span></div><div style="text-indent:18pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas, among others: future undiscounted cash flows and subsequent fair value estimates used to assess potential and measure any impairment of long-lived assets, including goodwill and intangible assets, and the measurement of right-of-use assets and lease liabilities, contingent consideration, stock-based compensation expense, accrued expenses, revenue, income taxes, and the assessment of the Company's ability to fund its operations for at least the next twelve months from the date of issuance of these financial statements.</span></div>
CY2020Q1	us-gaap	Equity Securities Fv Ni Cost EquitySecuritiesFvNiCost	20017000	USD
CY2020Q1	blue	Equity Securities Unrealized Gain EquitySecuritiesUnrealizedGain	0	USD
CY2020Q1	blue	Equity Securities Unrealized Loss EquitySecuritiesUnrealizedLoss	11667000	USD
CY2020Q1	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	8350000	USD
CY2020Q1	blue	Marketable Securities Amortized Cost MarketableSecuritiesAmortizedCost	681166000	USD
CY2020Q1	blue	Marketable Securities Unrealized Gains MarketableSecuritiesUnrealizedGains	3354000	USD
CY2020Q1	blue	Marketable Securities Unrealized Loss MarketableSecuritiesUnrealizedLoss	12792000	USD
CY2020Q1	us-gaap	Marketable Securities MarketableSecurities	671728000	USD
CY2019Q4	us-gaap	Equity Securities Fv Ni Cost EquitySecuritiesFvNiCost	20017000	USD
CY2019Q4	blue	Equity Securities Unrealized Gain EquitySecuritiesUnrealizedGain	0	USD
CY2019Q4	blue	Equity Securities Unrealized Loss EquitySecuritiesUnrealizedLoss	7147000	USD
CY2019Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	12870000	USD
CY2019Q4	us-gaap	Marketable Securities MarketableSecurities	910752000	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	USD
CY2019Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
CY2020Q1	us-gaap	Interest Receivable InterestReceivable	2900000	USD
CY2019Q1	us-gaap	Interest Receivable InterestReceivable	3600000	USD
CY2020Q1	blue	Interest Receivable Write Off InterestReceivableWriteOff	0	USD
CY2019Q1	blue	Interest Receivable Write Off InterestReceivableWriteOff	0	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	107072000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	1110000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	40614000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	15000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	147686000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	1125000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	67217000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	46000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	79618000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	45000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	146835000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	91000	USD
CY2020Q1	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	8400000	USD
CY2019Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	12900000	USD
CY2020Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0	USD
CY2020Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	0	USD
CY2020Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	194232000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	187749000	USD
CY2020Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	40312000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	36573000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	153920000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	151176000	USD
CY2020Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2604000	USD
CY2020Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	24018000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	44679000	USD
CY2020Q1	blue	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	25957000	USD
CY2019Q4	blue	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	23126000	USD
CY2020Q1	blue	Accrued Clinical And Contract Research Organization Costs Current AccruedClinicalAndContractResearchOrganizationCostsCurrent	21266000	USD
CY2019Q4	blue	Accrued Clinical And Contract Research Organization Costs Current AccruedClinicalAndContractResearchOrganizationCostsCurrent	16799000	USD
CY2020Q1	blue	Accrued Collaboration Research Costs Current AccruedCollaborationResearchCostsCurrent	19732000	USD
CY2019Q4	blue	Accrued Collaboration Research Costs Current AccruedCollaborationResearchCostsCurrent	27142000	USD
CY2020Q1	blue	Accrued Property Plant And Equipment Current AccruedPropertyPlantAndEquipmentCurrent	730000	USD
CY2019Q4	blue	Accrued Property Plant And Equipment Current AccruedPropertyPlantAndEquipmentCurrent	2354000	USD
CY2020Q1	blue	Accrued License And Milestone Fees AccruedLicenseAndMilestoneFees	768000	USD
CY2019Q4	blue	Accrued License And Milestone Fees AccruedLicenseAndMilestoneFees	300000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1827000	USD
CY2020Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	23016000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	25329000	USD
CY2020Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	118091000	USD
CY2019Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	141556000	USD
CY2020Q1	blue	Increase In Purchase Commitment Remaining Minimum Amount Committed IncreaseInPurchaseCommitmentRemainingMinimumAmountCommitted	57600000	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod	2200000	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod	2200000	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2500000	shares
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	32300000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	36300000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	36293000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	32341000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	36293000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	32341000	USD
CY2020Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	361800000	USD
CY2020Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M12D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5483000	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	116.30
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1147000	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	75.65
CY2020Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	20000	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	37.71
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	132000	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	148.55
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6478000	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	108.68
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3248000	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	99.92
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	6478000	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	108.68
CY2020Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	800000	USD
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8063000	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6527000	shares

Files In Submission

Name	View Source	Status
0001293971-20-000029-index-headers.html	Edgar Link	pending
0001293971-20-000029-index.html	Edgar Link	pending
0001293971-20-000029.txt	Edgar Link	pending
0001293971-20-000029-xbrl.zip	Edgar Link	pending
blue-20200331.htm	Edgar Link	pending
blue-20200331.xsd	Edgar Link	pending
blue-20200331xex311.htm	Edgar Link	pending
blue-20200331xex312.htm	Edgar Link	pending
blue-20200331xex321.htm	Edgar Link	pending
blue-20200331_cal.xml	Edgar Link	unprocessable
blue-20200331_def.xml	Edgar Link	unprocessable
blue-20200331_htm.xml	Edgar Link	completed
blue-20200331_lab.xml	Edgar Link	unprocessable
blue-20200331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BLUE
bluebird bio, Inc. Stock $blue

2020 Q1 Form 10-Q Financial Statement

#000129397120000029 Filed on May 11, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BLUE bluebird bio, Inc. Stock $blue

2020 Q1 Form 10-Q Financial Statement

#000129397120000029 Filed on May 11, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BLUE
bluebird bio, Inc. Stock $blue